Lineage Cell Therapeutics 10K/A 2022 Annual report (amended) | LCTX Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Good

New words: abetting, accident, administered, admission, Aeglea, aiding, al, alleged, AlloVir, Alto, Amin, Amplyx, Anderson, Anula, arrangement, asserted, assessed, assessment, Atara, atrophy, attestation, attract, Auditor, automatically, bio, BioAtla, BIOR, Biora, breach, brought, Buckinghamshire, budget, Cambridge, capitalist, captioned, Cardiff, Carlo, carrier, cast, catalyzing, Celldex, Celularity, Chancery, Chimerix, clause, Codagenix, collaboration, Collaborative, Columbia, committed, compensatory, compliant, composition, Compromise, concession, condition, conditioned, consideration, contract, Cook, Cooley, court, coverage, created, criteria, cum, DCH, DCPSA, de, death, decreased, defendant, degeneration, Delaware, delivering, denied, deny, detail, DGM, Dipti, directly, disability, disagreement, discharge, distinction, DLA, DRCOG, dry, DTx, duty, efficiently, entrepreneurial, entrepreneurship, evidence, Evolvence, exclusive, expressly, EXXclaim, facility, Fate, fault, federal, fewer, FFPM, fiduciary, Food, forfeited, Forma, Founder, fund, funded, Genentech, geographic, George, GMP, Goal, Gossamer, Gritstone, guidance, half, harbor, Harpoon, herewith, Hertfordshire, historic, Id, illustrated, IND, India, Infinity, injury, interpreted, Israel, IVERIC, Jaguar, Jayasuriya, Jill, Jounce, Juvenescence, Kevin, laude, lawsuit, Leap, LeBuhn, lesser, liability, London, lump, Lytx, Maaya, macular, Magenta, manner, matter, maximum, MeiraGTx, Microbiology, Monte, motivate, MRCGP, Narrative, Nasdaq, NHS, Nkarta, nominee, notice, notified, ocular, oncology, outperformed, package, Palo, Patrick, PC, pecuniary, Pharma, pharmacology, Phase, Phil, Philosophy, Piper, plaintiff, Poseida, preclinical, predetermined, premium, prepared, presumption, principle, promulgated, proof, purported, Reconciliation, recovery, relationship, release, restated, result, retain, return, reward, Richard, RMAT, Royal, safe, Samuel, satisfied, schedule, scheduled, settle, similarly, simulation, situated, Skyline, Society, Somaxon, spanning, Stipulation, Strawn, Street, study, successive, sum, summa, superior, supplemental, Synlogic, therapy, thereunder, trailing, Transnational, Trovagene, Trust, TVM, TXMD, tying, underlying, unexpired, unpaid, unused, unvested, venture, video, VLP, volume, voluntary, VP, wholly, Winston, Withum, Women, worldwide, wrongdoing, wrongful

Removed: account, administrative, Alameda, billing, biotime, bookkeeping, conducting, Farrell, fee, feet, invoiced, key, laboratory, located, month, office, payroll, personnel, Redmond, space, square, Stephen, work

	1.	I have reviewed this Amendment No. 1 on Form 10-K/A to the Annual Report on Form 10-K of Lineage Cell Therapeutics, Inc.; and

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: April 27, 2023

/s/ Brian M. Culley
Brian M. Culley
Chief Executive Officer
(Principal Executive Officer)

Lineage Cell Therapeutics (LCTX) 10-K/A2022 FY Annual report (amended)

Content analysis